Steps taken after granting the Marketing Authorisation 
For procedures finalised after 01 May 2004 please refer to module 8b. 
Scope 
Application 
number 
Type of 
modification1 
On 25 July 2002, the Marketing Authorisation Holder submitted a 
Type I Variation in accordance with Commission Regulation (EC) 
No. 542/95 as amended. The variation related to a change in the 
container shape.  
Urgent Safety Restriction on possible risk of serious hypersensitivity 
reactions including anaphylaxis and angioedema and serious skin 
reactions including Stevens-Johnson syndrome, toxic epidermal 
necrolysis, erythema multiforme and exfoliative dermatitis in 
patients treated with parecoxib. 
Change in or addition of manufacturing site(s) for part or all of the 
manufacturing process. 
The Urgent Safety Restriction dated 16 October 2002 concerning 
serious hypersensitivity reactions and serious skin reactions.  
Sections 4.3 (Contra-indications), 4.4 (Special warnings and special 
precautions for use) and 4.8 (undesirable effects) of the SPC have 
been amended. The Patient Leaflet was revised accordingly. 
Minor changes in manufacture of the medicinal product. 
Change in the batch size of finished product. 
Change in supplier of an intermediate compound used in 
manufacture of the active substance. 
Change in test procedure of active substance. 
Change in batch size of active substance. 
The MAH applied for changes to the PL not connected to the SPC. 
Update of sections 4.3 “Contraindications”, 4.4 “Special warnings 
and special precautions for use”, 4.5 “Pharmacodynamic 
Interactions”, 4.8 “Undesirable effects” and 5.1 “Pharmacodynamic 
properties” of the SPC of the medicinal product Dynastat following 
the request from the CPMP after the adoption of the opinion on the 
referral procedure under article 31 of Directive 2001/83/EEC, for all 
medicinal products containing celecoxib, etoricoxib, parecoxib, 
rofecoxib and valdecoxib. The package leaflet has been updated 
accordingly. 
The  MAH  applies  for  a  change  in  his  address  to  Sandwich,  Kent, 
CT13 9NJ, UK. 
Notification/ 
Opinion 
issued on2 
29.07.02 
Commission 
Decision 
Issued/amen
ded on 
16.10.02 
- 
20.11.02 
18.12.02 
19.04.03 
03.04.03 
03.04.03 
08.05.03 
03.04.03 
08.05.03 
14.01.04 
26.02.04 
- 
- 
- 
- 
- 
22.04.04 
I-0001 
- 
I-0002 
II-0003 
I-0004 
I-0005 
I-0006 
I-0007 
I-0008 
N-0009 
II-0011 
I 
- 
I 
II 
I 
I 
I 
I 
I 
N 
II 
I-0012 
IA 
19.04.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers 
to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a 
minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an 
Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 
March 1992. 
S refers to an annual reassessment. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA 
Notification date. The Commission Decision will be amended accordingly. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
                                                      
 
